nach oben

Erschienen in:

01.06.2015 | Research Article

SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation

verfasst von: Sujuan Yan, Yan Deng, Yong Qiang, Qinghua Xi, Rong Liu, Shuyun Yang, Jian Liu, Chunhui Tang, Jianxin Zhong, Yingying Wang

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

SYF2 is reported to be as a cell cycle regulator at the G1/S transition and encodes a nuclear protein that interacts with cyclin-D-type binding protein 1. In our study, we investigated the role of SYF2 in human epithelial ovarian cancer (EOC) progression. Western blot and immunohistochemistry analysis displayed that SYF2 was overexpressed in EOC tissues and EOC cell lines. In addition, the immunoreactivity of SYF2 was positively correlated with tumor grade and Ki-67 expression. In vitro, serum starvation-refeeding experiment and SYF2-siRNA transfection assay demonstrated that the expression of SYF2 was promoted in the proliferative progression of EOC cells, while knockdown of SYF2 expression decreased and inhibited cell growth rate of EOC cells. With all the results, we support that SYF2 might contribute to EOC progression via modulation of proliferation in EOC cells and would provide a novel therapeutic target of human EOC.

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81. doi:10.1016/j.ejca.2009.12.014.CrossRefPubMed

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. doi:10.3322/caac.20006.CrossRefPubMed

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.CrossRefPubMed

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.20138.CrossRefPubMed

Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719–25. doi:10.1038/nrc3144.CrossRefPubMedPubMedCentral

Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol. 2003;1:66. doi:10.1186/1477-7827-1-66.CrossRefPubMedPubMedCentral

Chu PC, Yang YC, Lu YT, Chen HT, Yu LC, Chang MS. Silencing of p29 affects DNA damage responses with UV irradiation. Cancer Res. 2006;66(17):8484–91. doi:10.1158/0008-5472.CAN-05-3229.CrossRefPubMed

Chang MS, Chang CL, Huang CJ, Yang YC. p29, a novel GCIP-interacting protein, localizes in the nucleus. Biochem Biophys Res Commun. 2000;279(2):732–7. doi:10.1006/bbrc.2000.3992.CrossRefPubMed

Dahan O, Kupiec M. Mutations in genes of Saccharomyces cerevisiae encoding pre-mRNA splicing factors cause cell cycle arrest through activation of the spindle checkpoint. Nucleic Acids Res. 2002;30(20):4361–70.CrossRefPubMedPubMedCentral

10.

Chen CH, Chu PC, Lee L, Lien HW, Lin TL, Fan CC, et al. Disruption of murine mp29/Syf2/Ntc31 gene results in embryonic lethality with aberrant checkpoint response. PLoS One. 2012;7(3):e33538. doi:10.1371/journal.pone.0033538.CrossRefPubMedPubMedCentral

11.

Vincent K, Wang Q, Jay S, Hobbs K, Rymond BC. Genetic interactions with CLF1 identify additional pre-mRNA splicing factors and a link between activators of yeast vesicular transport and splicing. Genetics. 2003;164(3):895–907.PubMedPubMedCentral

12.

Chu PC, Wang TY, Lu YT, Chou CK, Yang YC, Chang MS. Involvement of p29 in DNA damage responses and Fanconi anemia pathway. Carcinogenesis. 2009;30(10):1710–6. doi:10.1093/carcin/bgp204.CrossRefPubMed

13.

Ma W, Stafford LJ, Li D, Luo J, Li X, Ning G, et al. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis. J Cell Biochem. 2007;100(6):1376–86. doi:10.1002/jcb.21140.CrossRefPubMed

14.

Cui X, Liu Y, Wan C, Lu C, Cai J, He S, et al. Decreased expression of SERPINB1 correlates with tumor invasion and poor prognosis in hepatocellular carcinoma. J Mol Histol. 2014;45(1):59–68. doi:10.1007/s10735-013-9529-0.CrossRefPubMed

15.

Song W, Hu L, Li W, Wang G, Li Y, Yan L, et al. Oncogenic Fli-1 is a potential prognostic marker for the progression of epithelial ovarian cancer. BMC Cancer. 2014;14(1):424. doi:10.1186/1471-2407-14-424.CrossRefPubMedPubMedCentral

16.

Zhu J, Ji L, Zhang J, Yang L, Guan C, Wang Y, et al. Upregulation of SYF2 in esophageal squamous cell carcinoma promotes tumor cell proliferation and predicts poor prognosis. Tumour Biol J Int Soc Oncodev Biol Med. 2014. doi:10.1007/s13277-014-2305-2.

17.

Guo J, Yang L, Huang J, Liu X, Qiu X, Tao T, et al. Knocking down the expression of SYF2 inhibits the proliferation of glioma cells. Med Oncol. 2014;31(8):101. doi:10.1007/s12032-014-0101-x.CrossRefPubMed

18.

Xu W, Cao M, Zheng H, Tan X, Li L, Cui G, et al. Upregulation of SYF2 is associated with neuronal apoptosis caused by reactive astrogliosis to neuroinflammation. J Neurosci Res. 2014;92(3):318–28. doi:10.1002/jnr.23312.CrossRefPubMed

19.

Chang MS, Chen CY, Yeh HI, Fan CC, Huang CJ, Yang YC. Cloning, expression, and genomic organization of mouse mp29 gene. Biochem Biophys Res Commun. 2002;299(2):241–6.CrossRefPubMed

20.

Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem. 1989;264(23):13856–64.PubMed

21.

Pisani P, Parkin DM, Bray F, Ferlay J. Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18-29 (1999). International journal of cancer Journal international du cancer. 1999;83(6):870-3.

22.

Aris A. Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res. 2010;3:2. doi:10.1186/1757-2215-3-2.CrossRefPubMedPubMedCentral

23.

Cho H, Shin HY, Kim S, Kim JS, Chung JY, Chung EJ, et al. The role of S100A14 in epithelial ovarian tumors. Oncotarget. 2014;5(11):3482–96.CrossRefPubMedPubMedCentral

24.

Ben-Yehuda S, Dix I, Russell CS, McGarvey M, Beggs JD, Kupiec M. Genetic and physical interactions between factors involved in both cell cycle progression and pre-mRNA splicing in Saccharomyces cerevisiae. Genetics. 2000;156(4):1503–17.PubMedPubMedCentral

Titel: SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation
verfasst von: Sujuan Yan
Yan Deng
Yong Qiang
Qinghua Xi
Rong Liu
Shuyun Yang
Jian Liu
Chunhui Tang
Jianxin Zhong
Yingying Wang
Publikationsdatum: 01.06.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3111-1

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Letter regarding Xiao WZ et al. entitled “Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis”

CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer

Association between ADH1B and ADH1C polymorphisms and the risk of head and neck squamous cell carcinoma

FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein

Role of vitamin D receptor gene polymorphisms in pancreatic cancer: a case–control study in China

MicroRNA-10b and minichromosome maintenance complex component 5 gene as prognostic biomarkers in breast cancer

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie